Relief for neglected dermatological condition?

WESTLAKE VILLAGE, Calif.—Arcutis Biotherapeutics Inc., a late-stage biopharmaceutical company focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases and conditions, has completed enrollment of its Phase 2 proof-of-concept clinical trial evaluating roflumilast foam as a potential treatment for seborrheic dermatitis. 

 

Roflumilast foam is a once-daily topical foam formulation of a highly potent and selective phosphodiesterase type 4 inhibitor (PDE4 inhibitor) that the company is developing particularly to treat inflammatory dermatoses in hair-bearing areas of the body such as the scalp. The company anticipates topline data from this trial early in the fourth quarter of 2020. In addition, the company has begun enrollment in a long-term safety study of roflumilast foam in patients with seborrheic dermatitis.

 

“Seborrheic dermatitis is a common chronic skin disease that primarily occurs on the scalp, face and chest, and is one of the most neglected diseases in dermatology. There are more than six million sufferers in the U.S., many not knowing what it is and thinking it’s just dry skin, and more than 1.5 million who will receive a prescription topical treatment for this condition each year,” said Dr. Mark Jackson, a clinical professor of medicine (dermatology) at the University of Louisville. “I believe a significant need exists for novel non-steroidal therapies to treat this disease, particularly for patients who don’t adequately respond to existing treatments. The greatest reward as a physician comes from seeing patients with distressing chronic skin conditions improve with effective treatments. There is a significant need to find better treatment options for patients with seborrheic dermatitis and I look forward to seeing the results from this trial.”

 

“We are delighted with the strong support from investigators and the speed with which they enrolled this study, both of which underscore the demand for safe and effective new treatments for seborrheic dermatitis,” added Frank Watanabe, Arcutis’ president and CEO. “Roflumilast foam was developed as an easy-to-use once daily foam specifically to treat hair-bearing areas of the body like the scalp, where seborrheic dermatitis occurs, and where a cream, lotion, or ointment is not suitable.  A non-steroidal treatment is also preferable for treatment of the mid-face area, especially around the eyes, due to the risks associated with ocular steroid exposure. We believe roflumilast foam has the potential to be the first treatment with a new mechanism of action for seborrheic dermatitis in decades. We expect to announce topline data from this trial by early in the fourth quarter of this year.”

 

Roflumilast foam is a topical foam formulation of a highly potent and selective PDE4 inhibitor (roflumilast). Roflumilast has been approved by the FDA for systemic treatment to reduce the risk of exacerbations of chronic obstructive pulmonary disease (COPD) since 2011.  Roflumilast has shown greater potency (25- to 300-fold) than the two other FDA-approved PDE4 inhibitors.  PDE4 is an intracellular enzyme that increases the production of pro-inflammatory mediators and decreases production of anti-inflammatory mediators and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and COPD.  PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the topical treatment of atopic dermatitis or the systemic treatment of plaque psoriasis.

 

Arcutis believes roflumilast foam has significant potential as a treatment for seborrheic dermatitis. Roflumilast foam is nearly identical to ARQ-151 (topical roflumilast cream), Arcutis’ investigational topical cream PDE4 inhibitor that has demonstrated symptomatic improvement and a favorable tolerability profile in the Company’s clinical trials in plaque psoriasis, as well as encouraging results in atopic dermatitis.